NeXstar Pharmaceuticals

NeXstar Pharmaceuticals' AmBisome Is Subject Of Two Talks At ICAAC

AmBisome, a liposomal formulation of amphotericin B, has been shown to sterilize the CSF significantly earlier than conventional amphotericin B, with at least equal clinical efficacy and lower nephrotoxicity. In a randomized multi-center study, low-dose AmBisome therapy produced a response rate of 68% in treating invasive aspergillosis.

SourceNeXstar Pharmaceuticals·DateSep 17, 1996

NeXstar Creates Aptamer-Based Diagnostic Assay; Assay Aids Clinical Development Of VEGF Inhibitor

NeXstar Pharmaceuticals has created an aptamer-based diagnostic assay for its VEGF inhibitor, enhancing cancer treatment possibilities. The ELONA system uses an aptamer to detect small amounts of clinically important substances, overcoming limitations of traditional antibodies in diagnostic assays.

SourceNeXstar Pharmaceuticals·DateAug 6, 1996